¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"product line management"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • end product
    ÃÖÁ¾»ê¹°
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • intermediate product
    Áß°£»ê¹°
  • leukocyte-depleted blood product
    ¹éÇ÷±¸Á¦°ÅÇ÷¾×Á¦Á¦
  • marine product
    ÇØ»ê¹°
  • product
    1. »ê¹° 2. »ý¼º¹°
  • split product
    ºÐ¸®»ê¹°
  • substitution product
    ġȯ»ý¼º¹°
  • anocutaneous line
    Ç×¹®ÇǺμ±
  • anterior axillary line
    ¾Õ°Üµå¶û¼±, Àü¾×¿Í¼±
  • arcuate line
    Ȱ²Ã¼±
  • axillary line
    °Üµå¶û¼±, ¾×¿Í¼±
  • blood line
    Ç÷Á·°è, Ç÷Åë
  • blue line
    û»ö¼±
  • cleavage line
    ºÐÇÒ¼±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transverse line
    °¡·Î¼±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • decay product
    ºØ±«»ê¹°
  • degradation product
    ºÐÇØ»ê¹°
  • end product
    ÃÖÁ¾»ê¹°
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • intermediate product
    Áß°£»ê¹°, Áß°£´ë»ç¹°
  • leukocyte-depleted blood product
    ¹éÇ÷±¸Á¦°ÅÇ÷¾×Á¦Á¦
  • marine product
    ÇØ»ê¹°
  • product
    »ý¼º¹°, »ê¹°
  • split product
    ºÐ¸®»ê¹°
  • substitution product
    ġȯü
  • anocutaneous line
    Ç×¹®ÇǺμ±
  • arcuate line
    Ȱ²Ã¼±
  • mesiolingual line angle
    ¾ÈÂÊÇôÂʼ±°¢
  • mesioocclusal line angle
    ¾ÈÂʸ¹°¸²¸é¼±°¢, ¾ÈÂʱ³Çո鼱°¢
  • plane-line articulator
    Æò¸é¼±±³ÇÕ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • Haabs line
    ÇϺ꼱
  • Hudson-Staehli line
    Çãµå½¼-½ºÅŸ®¼±
  • Hudsons pigmented line
    Çãµå½¼»ö¼Ò¼±
  • KCL =keratoconus line
    ¿ø»Ô°¢¸·¼±.
  • Kerley s A line
    Äø® A¼±.
  • Kerley s B line
    Äø® B¼±.
  • Kerley s C line
    Äø® C¼±.
  • Kerleys A line
    Äø® A¼±
  • Kerleys B line
    Äø® B¼±
  • Kerleys C line
    Äø® C¼±
  • Kerleys D line
    Äø® D¼±
  • Langer line
    ¶û°Å¼±
  • Mees line
    ¹ÌÁî¼±
  • Sampaolesis line
    »ïÆú·¹½Ã»ö¼Ò¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • self-management skills training
    ÀÚ±â°ü¸®±â¼ú ÈÆ·Ã
  • self-management techniques
    ÀÚ±â°ü¸®±â¼ú
  • stress management
    ½ºÆ®·¹½º°ü¸®(~η×â).
  • total quality management
    Á¾ÇÕÀû Áú°ü¸®.
  • addition product
    ºÎ°¡»ý¼º¹°(¡­ßæà÷Úª).
  • assimilation product
    µ¿È­»ý»ê¹°.
  • biological product
    »ý¹°ÇÐÀû Á¦Á¦(¡­ð²ð¥).
  • blood product
    Ç÷¾×Á¦Á¦.
  • by-product
    ºÎ»ê¹°.
  • decay product
    ºØ±«»ý¼º
  • degradation product
    ºÐÇØ»ê¹°(ÝÂú°ß§Úª)
  • distortion product otoacoustic emission
    º¯Á¶ÀÌÀ½Çâ¹Ý»ç
  • end product
    ÃÖÁ¾»ê¹°.»ýÈ­Á¾»ê¹°.
  • fibrin degradation product
  • intermediate product
    Áß°£»ý¼º¹°(¡­ßæà÷Úª), Áß°£»ê¹°, Áß°£´ë»ç¹°.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Semilunar line
    ¹Ý´Þ¼±
    [¿¾ ¿ë¾î] ¹Ý¿ù¼±
  • Terminal line
    ºÐ°è¼±
    [¿¾ ¿ë¾î] ºÐ°è¼±
  • Midclavicular line
    ºøÀåÁß°£¼±
    [¿¾ ¿ë¾î] À¯µÎ¼±
  • Epiphyseal line
    »À³¡¼±
    [¿¾ ¿ë¾î] °ñ´Ü¼±
  • Incremental line of dentin
    »ó¾ÆÁú¼ºÀå¼±
    [¿¾ ¿ë¾î] »ó¾ÆÁú¼ºÀå¼±
  • Incremental line of cementum
    ½Ã¸àÆ®Áú¼ºÀå¼±
    [¿¾ ¿ë¾î] ½Ã¸àÆ®Áú¼ºÀå¼±
  • Inferior temporal line
    ¾Æ·¡°üÀÚ¼±
    [¿¾ ¿ë¾î] ÇÏÃøµÎ¼±
  • Inferior nuchal line
    ¾Æ·¡¸ñ´ú¹Ì¼±
    [¿¾ ¿ë¾î] ÇÏÇ×(¸ñ´ú¹Ì)¼±
  • Inferior gluteal line
    ¾Æ·¡º¼±â±Ù¼±
    [¿¾ ¿ë¾î] Çϵбټ±
  • Medial supracondylar line
    ¾ÈÂʰüÀýÀ¶±âÀ§¼±
    [¿¾ ¿ë¾î] ³»Ãø°ú»ó¼±
  • Anterior axillary line
    ¾Õ°Üµå¶û¼±
    [¿¾ ¿ë¾î] Àü¾×¿Í¼±
  • Anterior gluteal line
    ¾Õº¼±â±Ù¼±
    [¿¾ ¿ë¾î] ÀüµÐ±Ù¼±
  • Midsternal line
    ¾ÕÁ¤Áß¼±
    [¿¾ ¿ë¾î] ÀüÁ¤Áß¼±
  • Scapular line
    ¾î±ú»À¼±
    [¿¾ ¿ë¾î] °ß°©¼±
  • Superior temporal line
    À§°üÀÚ¼±
    [¿¾ ¿ë¾î] »óÃøµÎ¼±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • germ line
    ¹èÀÚ°è¿­(ÛÏí­Í§Öª)
  • germ-line theory
    ¹èÀÚ°è¿­ ÀÌ·Ð(ÛÏí­Í§Öª×âÖå)
  • isologous cell line
    µ¿Á¾¼¼Æ÷ÁÖ(ÔÒðúá¬øàñ»)
  • layer line
    Ãþ¼±(öµàÊ)
  • line
    °èÅë(ͧ÷Ö)
  • line emission
    ¼±¹æÃâ(àÊÛ¯õó)
  • line spectrum
    ¼±(àÊ)½ºÆåÆ®·Ò
  • line splitting
    ¼±ºÐÇÒ(àÊÝÂùÜ)
  • pure line
    ¼ø¼ö °èÅë(ͧ÷Ö)
  • regression line
    ȸ±Í¼±(üÞÏýàÊ)
  • T cell line
    T ¼¼Æ÷ÁÖ(á¬øàñ»)
  • Z line
    Z ¼±(àÊ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • line pair/mm
    mm´ç ¼±ÀǼö
  • oblique line
    °æ»ç¼±, »ç¼±
  • off-line
    ¿ÀÇÁ¶óÀÎ
  • O-M [=orbitomeatal] line
    ¾È¿ÜÀ̵µ¼±
  • on-line
    ¿Â¶óÀÎ
  • orbitomeatal [=O-M] line
    ¾È¿ÜÀ̵µ¼±
  • paravertebral line
    ôÃßÁÖÀ§¼±
  • pectineal line
    Ä¡°ñ±Ù¼±
  • prosthesis cement lucent line
    Àΰø¹°½Ã¸àÆ® ¹æ»ç¼ºÅõ°ú¼±
  • reinforcement line
    °­È­¼±
  • waist line
    Ç㸮µÑ·¹, ¿äÀ§
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LCL Levinthal-Coles-Lillie [body]; lower confidence limit; lower control limit; lymphoblastoid cell line...
MCL maximum containment laboratory; medial collateral ligament; midclavicular line; midcostal line; mini...
HM hand movements; health maintenance; heart murmur; hemifacial microsomia; Holter monitoring; home man...
MIMS medical information management system; medical inventory management system
PMP pain management program; patient management program; patient medication profile; peripheral myelin p...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DBMS Data Base Management System
DM Disease Management
DPOAE Distorsion product otoacoustic emissions
DP Distortion Product
DPE Distortion Product Emission
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • orthodontic management
    ±³Á¤ Ä¡·á
  • personal management
    ÀÎ»ç °ü¸®
  • pharmacologic management
    ¾à¹° Ä¡·á, ¾à¹° ¿ä¹ý
  • postoperative management
    ¼ö¼úÈÄ °ü¸®, ¼úÈÄ °ü¸®¹ý
  • postoprative management
    ¼ö¼ú ÈÄ °ü¸®
  • postsurgical management
    ¼ö¼úÈÄ °ü¸®
  • risk management
    ¼úÀÚÀÇ ¾ÈÀü ¼öÄ¢
  • space management
    °ø°£ °ü¸®
  • ward management
    º´½Ç °ü¸®, º´µ¿ °ü¸®
  • alveolar line
    Ä¡Á¶¼±, »ó¾Ç¼±
  • alveolar ridge line
    Ä¡Á¶Á¤ ¼±
  • base line
    ±â¼±, ±âÀú¼±, ¹ÙÅÁ¼±
    ¹ÌÁ¤ÀÇ ¾çÀ̳ª °ªÀ» ÃøÁ¤ ¶Ç´Â ÆòÁ¤ÇÏ´Â µ¥ ¾²ÀÌ´Â ±âº»ÀÇ ¾ç ¶Ç´Â °ª.
  • base line shift
    ±âÁؼ± º¯À§
  • blood line
    Ç÷Á·, Ç÷Á·°è
  • Camper's line
    įÆÛ ¼±
    ºñÀÍÀÇ Çϴܰú ¿ÜÀ̵¹±âÀÇ »ó¿¬À» ¿¬°áÇÏ´Â ¼±.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
substitution product A product obtained by replacing one atom or group in a molecule with another atom or group.
(05 Mar 2000)
double product The product of systolic blood pressure multiplied by the heart frequency; a measure of heart work load.
See: Robinson index.
(05 Mar 2000)
trade name product <pharmacology> Trademarked proprietary preparations containing the generic substance. Some foreign trade name products have been selectively included here due to the relative popularity of the generic medication.
(17 Mar 1998)
end product <biochemistry> The final product of after a series of reactions with enzymes in a biochemical metabolic pathway has taken place.
(09 Oct 1997)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
end product repression Catabolite repression in which the catabolite is an end product of a particular pathway.
(05 Mar 2000)
fission product An atomic species produced in the course of the fission of a larger atom such as 235U.
(05 Mar 2000)
adaptive management A continuing process of action-based planning, monitoring, researching, evaluating, and adjusting with the objective of improving implementation and achieving the goals of the selected alternative.
(05 Dec 1998)
adaptive management area Landscape units designated for development and testing of technical and social approaches to achieving desired ecological, economic, and other social objectives.
(05 Dec 1998)
management activities Planned activities initiated by land managers to meet the desired future condition for an area. Management activities may include thinning, timber harvest, prescribed burning, tree planting, and other activities.
(05 Dec 1998)
management area Management areas are specific geographical areas defined by a forest plan. Each management area has a set of objectives and a management prescription unique to it.
(05 Dec 1998)
management audit Management review designed to evaluate efficiency and to identify areas in need of management improvement within the institution in order to ensure effectiveness in meeting organizational goals.
(12 Dec 1998)
management indicator species A species whose habitat requirements most reflect those of the species community in the habitat of concern, usually used to indicate habitat quality and to predict future conditions.
(09 Oct 1997)
management information systems Systems designed to provide information primarily concerned with the administrative functions associated with the provision and utilization of services; also includes program planning, etc.
(12 Dec 1998)
management plan A plan guiding overall management of an area administered by a federal or state agency. A management plan usually includes objectives, goals, standards and guidelines, management actions, and monitoring plans.
(05 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • middle management
    Áß°£ °ü¸®ÀÚÃþ 9
  • top management
    (±â¾÷ÀÇ) ÃÖ°í°æ¿µ °ü¸®Á¶Á÷
  • by-product
    ºÎ»ê¹°
  • product
    (º¹¼ö)»ý»ê¹°,¼º°ú
  • end product
    ¿¬¼Ó º¯È­ÀÇ ÃÖÁ¾°á°ú;ÃÖÁ¾ »ý¼º¹°
  • fission product
    Çٺп­ »ý¼º¹°
  • generic product
    »óÇ¥¾øÀÌ ÀϹݸíÀ¸·Î ÆÇ¸ÅµÇ´Â »óǰ
  • gross domestic product
    ±¹³» ÃÑ»÷»ê(GDP)
  • gross national product
    ±¹¹Î ÃÑ»ý»ê D
  • inner product
    ³»Àû
  • national product
    (°æ)(¿¬°£)±¹¹Î»ý»ê(cf.GNP)
  • net domestic product
    ±¹³» ¼ø»ý»ê
  • net national product
    ±¹¹Î¼ø»ý»ê
  • new product
    ½ÅÁ¦Ç°(»õ·Î¿î°ÍÀ¸·Î ÀÎÁ¤µÈ Á¦Ç° ¶Ç´Â ¼­ºñ½º)
  • parity product
    ÆÐ¸®Æ¼ Á¦Ç°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á